pirfenidone has been researched along with Kidney Diseases in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Karmalawy, AA; Antar, SA; El-Azab, MF; Hazem, RM; Nafea, YK; Saleh, MA | 1 |
| Isaka, Y | 1 |
| Tampe, D; Zeisberg, M | 1 |
| Funke-Chambour, M; Geiser, T | 1 |
| Gu, C; Li, Z; Liu, X; Nie, Y; Wang, B; Wang, Q; Wen, J | 1 |
| Cho, ME; Kopp, JB | 1 |
| Shah, SV | 1 |
| Kossen, K; Pan, L; Ruhrmund, DW; Schaefer, CJ; Seiwert, SD | 1 |
| Al-Bayati, MA; Giri, SN; Margolin, SB; Mohr, FC; Xie, Y | 1 |
| Bao, L; Cho, IH; Hyun, BH; Kim, YJ; Lee, CH; Margolin, SB; Park, HS; Park, YH | 1 |
| Al-Bayati, MA; Du, X; Giri, SN; Margolin, SB; Mohr, FC; Schelegle, E | 1 |
| Bicknell, GR; Brook, NR; Nicholson, ML; Waller, JR | 1 |
| Shihab, FS | 1 |
| Cohen, EP; Fish, BL; Moulder, JE; Raife, TJ; Regner, KR | 1 |
| Andoh, TF; Bennett, WM; Shihab, FS; Yi, H | 1 |
6 review(s) available for pirfenidone and Kidney Diseases
| Article | Year |
|---|---|
Targeting TGF-β Signaling in Kidney Fibrosis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Fibrosis; Humans; Kidney; Kidney Diseases; Molecular Targeted Therapy; Pyridones; Signal Transduction; Transforming Growth Factor beta | 2018 |
Potential approaches to reverse or repair renal fibrosis.
Topics: Anti-Inflammatory Agents; Bone Morphogenetic Protein 7; Connective Tissue Growth Factor; Disease Progression; Endothelin-1; Epigenesis, Genetic; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Microcirculation; Phosphodiesterase Inhibitors; Pyridones; Transforming Growth Factor beta | 2014 |
[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Kidney Diseases; Pyridones; Respiratory System Agents; Treatment Outcome | 2016 |
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Drug Evaluation; Fibrosis; Humans; Kidney; Kidney Diseases; Pyridones | 2010 |
Progress toward novel treatments for chronic kidney disease.
Topics: Amides; Anticoagulants; Antihypertensive Agents; Bicarbonates; Chronic Disease; Enzyme Inhibitors; Fumarates; Glycosaminoglycans; Humans; Indoles; Iron Chelating Agents; Kidney Diseases; Kidney Failure, Chronic; Maleimides; Pentoxifylline; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridones; Renin; Renin-Angiotensin System | 2010 |
Antifibrotic activities of pirfenidone in animal models.
Topics: Administration, Oral; Animals; Cardiomyopathies; Disease Models, Animal; Extracellular Matrix Proteins; Humans; Kidney Diseases; Liver Cirrhosis; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta | 2011 |
9 other study(ies) available for pirfenidone and Kidney Diseases
| Article | Year |
|---|---|
Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Doxorubicin; Female; Fibrosis; Kidney Diseases; Mice; Pyridones; Vitamin D; Vitamins | 2022 |
Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.
Topics: Actins; Animals; Antigens, CD; Cadherins; Cell Line; Collagen Type I; Collagen Type III; Disease Models, Animal; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Fibronectins; Fibrosis; Humans; JNK Mitogen-Activated Protein Kinases; Kidney Diseases; Kidney Tubules, Proximal; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridones; Rats, Sprague-Dawley; Renal Agents; S100 Calcium-Binding Protein A4; Transforming Growth Factor beta1; Ureteral Obstruction | 2017 |
Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Drug Interactions; Fibrosis; Kidney Diseases; Male; Pyridones; Rats; Rats, Sprague-Dawley; Vanadates | 2002 |
Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis; Kidney; Kidney Diseases; Male; Mice; Proteinuria; Pyridones; Sclerosis; Time Factors | 2003 |
Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Body Weight; Diet; Doxorubicin; Eating; Heart Diseases; Hemodynamics; Kidney; Kidney Diseases; Male; Myocardium; Pyridones; Rats; Rats, Sprague-Dawley; Respiratory Function Tests | 2004 |
The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Collagen Type III; Collagenases; Fibrosis; Gene Expression Regulation, Enzymologic; Immunosuppressive Agents; Kidney Diseases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrolimus; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta | 2005 |
Do we have a pill for renal fibrosis?
Topics: Chronic Disease; Fibrosis; Humans; Kidney; Kidney Diseases; Pyridones; Tablets | 2007 |
Retinoic acid exacerbates experimental radiation nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Extracellular Matrix; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Kidney Failure, Chronic; Proteinuria; Pyridones; Radiation Injuries, Experimental; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidines; Tretinoin; Uremia; Whole-Body Irradiation | 2002 |
Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biglycan; Calcinosis; Creatinine; Cyclosporine; Extracellular Matrix Proteins; Humans; Immunohistochemistry; Immunosuppressive Agents; Kidney; Kidney Diseases; Kidney Tubules; Male; Proteoglycans; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription, Genetic; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2002 |